Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating the safety and efficacy of oral APL-1202 in combination with tislelizumab vs tislelizumab alone as neoadjuvant therapy for muscle in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• APL-1202 (APL-1202)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Jiangsu Yahong Meditech Co., Ltd aka Asieris | Conditions: Muscle Invasive Bladder Cancer | Phase 1, Phase 2 | Status: UNKNOWN